LNTH News and Press, Lantheus Holdings Inc. From 02/04/21

Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and p...

Lantheus ([[LNTH]] +4.0%) has filed a Drug Master File with the FDA for NM-01, a PD-L1 imaging biomarker, and will begin making the biomarker available to academic centers and pharmaceutical companies for use in immuno-oncology trials in 2021.NM-01 is a proprietary radiopharmaceutical bi...

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced ...

Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus. Balance sheet safety, profit margins, revenue growth, and current valuations are better than industry average. A large short interest position and a nu...

Under priority review status, the FDA has accepted Lantheus' ([[LNTH]] +3.5%) marketing application for PyL (18F-DCFPyL), a prostate specific membrane antigen-targeted positron emission tomography imaging agent for prostate cancer.Action date has been assigned of May 28, 2021. The FDA ha...

PDUFA action date of May 28, 2021 assigned by U.S. Food and Drug Administration Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture...

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has...

Lantheus Holdings (LNTH) , the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals (PGNX) entered into a stock purchase agreement to sell its Puerto Rico radiopharmacy and positron emission tomography ((PET)) manufacturing facility ((PMF)) to PharmaLo...

Transaction Extends Relationship with Strategic Partner Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercializati...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and p...